Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.37 |
| ▸ | RXRA | P19793 | 1/20 | 0.37 |
| ▸ | RXRB | P28702 | 1/20 | 0.37 |
| ▸ | RXRG | P48443 | 1/20 | 0.37 |
| ▸ | MGLL | Q99685 | 1/20 | 0.37 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20530673 | 0.93 | KMT2A (0.42) | PTGDR2KMT2AMEN1ATMEPHX2 | |
| SCHEMBL20530627 | 0.88 | EPHX2 (0.47) | KMT2AEPHX2CHRM3OPRD1 | |
| SCHEMBL30466807 | 0.86 | PTGDR2 (0.41) | PTGDR2KMT2AMEN1ATMEPHX2 | |
| SCHEMBL20530646 | 0.86 | PTGDR2 (0.41) | PTGDR2KMT2AMEN1ATMEPHX2 | |
| SCHEMBL29639572 | 0.86 | EPHX2 (0.43) | KMT2AEPHX2CHRM3OPRD1 | |
| SCHEMBL20530629 | 0.86 | CHRM3 (0.45) | KMT2AEPHX2MDM2CHRM3 | |
| SCHEMBL20530645 | 0.84 | CHRM3 (0.44) | KMT2AEPHX2MDM2CHRM3 | |
| SCHEMBL29639579 | 0.84 | EPHX2 (0.41) | KMT2AMEN1ATMEPHX2MDM2 | |
| SCHEMBL20530648 | 0.79 | EPHX2 (0.40) | PTGDR2KMT2AMEN1ATMEPHX2 | |
| SCHEMBL30466808 | 0.79 | EPHX2 (0.40) | PTGDR2KMT2AMEN1ATMEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3609905-B1 | PEPTIDE MACROCYCLES AND USE THEREOF IN THE TREATMENT OF BACTERIAL INFECTIONS | HOFFMANN LA ROCHE (CH) | 2022-06-08 | — | — | EP | disclosed |
| US-11091514-B2 | Peptide macrocycles and use thereof in the treatment of bacterial infections | HOFFMANN-LA ROCHE INC. (US) | 2021-08-17 | — | — | US | disclosed |
| EP-3609905-A1 | PEPTIDE MACROCYCLES AND USE THEREOF IN THE TREATMENT OF BACTERIAL INFECTIONS | H. Hoffnabb-La Roche Ag (CH) | 2020-02-19 | — | — | EP | disclosed |
| US-20200040032-A1 | PEPTIDE MACROCYCLES AND USE THEREOF IN THE TREATMENT OF BACTERIAL INFECTIONS | HOFFMANN-LA ROCHE INC. (US) | 2020-02-06 | — | — | US | disclosed |
| WO-2018189063-A1 | PEPTIDE MACROCYCLES AND USE THEREOF IN THE TREATMENT OF BACTERIAL INFECTIONS | F. HOFFMANN-LA ROCHE AG (CH) | 2018-10-18 | — | — | WO | disclosed |
| EP-3388445-A1 | PEPTIDE MACROCYCLES AND USE THEREOF IN THE TREATMENT OF BACTERIAL INFECTIONS | F. Hoffmann-La Roche AG (CH) | 2018-10-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11091514-B2 | Peptide macrocycles and use thereof in the treatment of bacterial infections | VIP, NPY5R, CXCR3 | PTGDR2 1519/4885KMT2A 4691/4885MEN1 740/4885 |
| US-20200040032-A1 | PEPTIDE MACROCYCLES AND USE THEREOF IN THE TREATMENT OF BACTERIAL INFECTIONS | VIP, NPY5R, CXCR3 | PTGDR2 1519/4885KMT2A 4691/4885MEN1 740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.